People: Ariad Pharmaceuticals, Inc. (ARIA.O)

ARIA.O on Consolidated Issue listed on NASDAQ Global Market

2.35USD
9 Feb 2010
Price Change (% chg)

$0.12 (+5.38%)
Prev Close
$2.35
Open
--
Day's High
$2.35
Day's Low
$2.18
Volume
2,415,364
Avg. Vol
1,257,294
52-wk High
$3.48
52-wk Low
$0.97

view people for:

Summary

Name Age Since Current Position
Berger, Harvey 58 2004 Chairman of the Board, President, Chief Executive Officer
Fitzgerald, Edward 54 2002 Chief Financial Officer, Senior Vice President, Treasurer
Clackson, Timothy 43 2003 Senior Vice President, Chief Scientific Officer
Keane, Raymond 50 2009 Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Iuliucci, John 66 2003 Senior Vice President, Chief Development Officer
Berstein, David 56 2008 Senior Vice President, Chief Intellectual Property Officer
Dodion, Pierre 54 2008 Senior Vice President, Chief Medical Officer
Ros, Matthew 42 2009 Senior Vice President - Commercial Operations
Bollag, Daniel 48 2009 Senior Vice President - Regulatory Affairs and Quality
Lavidas, Athanase 61 2008 Lead Independent Director
LaMarche, Jay 62 2000 Director
Radaelli, Massimo 51 2008 Director
Wilson, Wayne 60 2008 Director
Smyth, A. Collier 63 2009 Director
» Insider Trading

Biographies

Name Description
Berger, Harvey Harvey J. Berger, M.D., is Chairman of the Board, President, Chief Executive Officer of Ariad Pharmaceuticals, Inc. Harvey J. Berger, who has served on Board of Directors since April 1991, is principal founder and has served as Chairman of the Board and Chief Executive Officer since April 1991, and served as President from April 1991 to September 2003 and from December 2004 to present. From 1986 to 1991, Dr. Berger held a series of senior management positions at Centocor, Inc., a biotechnology company, including Executive Vice President and President, Research and Development Division. He also has held senior academic and administrative appointments at Emory University, Yale University and the University of Pennsylvania and was an Established Investigator of the American Heart Association, Inc. Dr. Berger is a member of the Dean’s Council of Yale University School of Medicine. Dr. Berger received his A.B. degree in Biology from Colgate University and his M.D. degree from Yale University School of Medicine and did further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.
Fitzgerald, Edward Edward M. Fitzgerald has served as Senior Vice President, Chief Financial Officer and Treasurer of Ariad Pharmaceuticals, Inc. since May 2002. From 1998 to April 2002, he served as Senior Vice President, Chief Financial Officer and Secretary at AltaRex Corp., a biotechnology company. From 1992 to 1997, Mr. Fitzgerald held various management positions at BankBoston Corp., a financial services and commercial banking company. From 1989 to 1992, he was a partner at Arthur Andersen & Co. in the audit and business advisory practice. Previously, from 1978 to 1988, he also was at Arthur Andersen & Co. Mr. Fitzgerald received his B.S. degree in accounting and M.B.A. degree in finance from Babson College.
Clackson, Timothy Timothy P. Clackson, Ph.D. has served as Senior Vice President and Chief Scientific Officer of Ariad Pharmaceuticals, Inc. since September 2003. Previously, he served as Senior Vice President, Science and Technology from June 2002 to September 2003, as Vice President, Gene Therapy and Genomics from June 2000 to June 2002, as Director, Gene Therapy from August 1999 to June 2000 and as Department Head, Gene Therapy Biology from March 1999 to August 1999. Prior to joining in December 1994, Dr. Clackson was a postdoctoral fellow at Genentech, Inc., a biotechnology company from 1991 to 1994, where he studied the molecular basis for human growth hormone function. Dr. Clackson received his B.A. degree in Biochemistry from the University of Oxford. Dr. Clackson received his Ph.D. degree in Biology from the University of Cambridge, for research conducted at the MRC Laboratory of Molecular Biology into antibody engineering and the development of phage display technology.
Keane, Raymond Raymond T. Keane, Esq. has served as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer of Ariad Pharmaceuticals, Inc. since January 2009 and was previously Vice President, General Counsel and Chief Compliance Officer since May 2008. Prior to joining ARIAD, Mr. Keane spent 20 years with Bristol-Myers Squibb Company (BMS), most recently as Senior Counsel, Worldwide Medicines and previously as lead counsel to various therapeutic divisions. While at BMS, he had primary legal responsibility for the commercialization and launch of seven BMS products. Before joining BMS in 1988, Mr. Keane was an associate with the law firms of Wilson, Elser, Moskowitz, Edelman & Dicker from 1987 to 1988 and Martin, Clearwater and Bell from 1984 to 1987. He received his J.D. degree from Fordham University School of Law and his B.A. degree in Economics from Fordham University.
Iuliucci, John John D. Iuliucci, Ph.D. has served as Senior Vice President and Chief Development Officer of Ariad Pharmaceuticals, Inc. since September 2003. Previously, he served as Senior Vice President, Drug Development from January 1999 to September 2003, as Vice President, Drug Development from October 1996 to December 1998 and as Vice President, Preclinical Development from June 1992 to September 1996. Prior to joining , Dr. Iuliucci was Director of Preclinical Pharmacology and Toxicology at Centocor, Inc., a biotechnology company, from 1984 to 1992. From 1975 to 1984, Dr. Iuliucci headed the Drug Safety Evaluation Department at Adria Laboratories, a pharmaceutical company. He was a Senior Toxicologist at the Warner-Lambert Pharmaceutical Research Institute from 1972 to 1975. Dr. Iuliucci received his B.S. degree in Pharmacy and M.S. and Ph.D. degrees in Pharmacology from Temple University.
Berstein, David David L. Berstein, Esq. has served as Senior Vice President and Chief Intellectual Property Officer of Ariad Pharmaceuticals, Inc. since May 2008. Mr. Berstein also served as Senior Vice President and Chief Patent Counsel from June 2003 until June 2007 and Vice President and Chief Patent Counsel from September 1993 to June 2000. From July 2007 until his return to ARIAD in May 2008, Mr. Berstein was Senior Vice President and Chief Patent Counsel for Tempo Pharmaceuticals, Inc., a biotechnology company. During this time period, he was a consultant to ARIAD on intellectual property matters. From 1990 through 1993, Mr. Berstein was Patent Counsel at BASF Bioresearch Corporation, a biotechnology company, where he was responsible for intellectual property matters, including patents and licensing. From 1985 to 1990, Mr. Berstein was a patent attorney at Genetics Institute, Inc., a biotechnology company, where he was involved in various aspects of the patent process from patent procurement through litigation. Mr. Berstein joined Genetics Institute from the law firm of Cooper & Dunham. Mr. Berstein received his B.S. degree from the University of Michigan and his J.D. degree from Fordham University School of Law.
Dodion, Pierre Pierre F. Dodion, M.D. has served as Senior Vice President, Chief Medical Officer of Ariad Pharmaceuticals, Inc. since April 2008. Previously, he served as Senior Vice President, Oncology since June 2007. From 2006 to 2007, Dr. Dodion served as Executive Director, Oncology at Pfizer Inc. From 2002 to 2006, he held senior positions at Novartis in the Oncology Business Unit, most recently as Executive Director, Global Strategy and Global Marketing. From 1997 to 2002, Dr. Dodion served as Medical Director and later as Senior Medical Director at Aventis. Prior to Aventis, he held medical and scientific positions at UCB S.A. and Roche Pharmaceuticals. Previously he held positions at Institut Jules Bordet at the Free University of Brussels and the National Cancer Institute. Dr. Dodion received his M.D. from the Free University of Brussels in Belgium and his M.B.A. degree from St Joseph University in Philadelphia, Pennsylvania.
Ros, Matthew Matthew E. Ros has served as Senior Vice President, Commercial Operations of Ariad Pharmaceuticals, Inc. since January 2009. He previously served as Vice President, Commercial Operations and Vice President, Oncology Marketing from November 2007 through December 2008. From 1990 to 2007, Mr. Ros held a series of senior sales, marketing and operations management positions at Bristol-Myers Squibb Company (BMS), most recently Senior Director and U.S. Commercial Lead responsible for the launch and commercialization of oncology products. Mr. Ros’ previous positions at BMS included Director, Oncology Franchise Planning and Development; Director, Oncology Global Marketing; and Director, Sales Training and Promotion. Mr. Ros received his B.Sc. from the State University of New York.
Bollag, Daniel Daniel M. Bollag, Ph.D. has served as Senior Vice President, Regulatory Affairs and Quality of Ariad Pharmaceuticals, Inc. since January 2009. He previously served as Vice President, Regulatory Affairs, for Genzyme Corporation, a biotechnology company, from 2006 to 2008. From 2002 to 2006, Dr. Bollag held multiple positions at Sanofi-Aventis Pharmaceuticals, including Associate Vice President, Global Regulatory Domain Head, Associate Vice President, Global Regulatory Therapeutic Area Head, and Director, U.S. Regulatory Liaison. Dr. Bollag also served as Director, Project Planning and Management at the Bristol-Myers Squibb Pharmaceutical Research Institute from 2000 to 2002. Earlier in his career, from 1991-2000, he held positions at Merck Research Laboratories. Dr. Bollag received his B.S. degree in Science and B.A. in French at Pennsylvania State University and his Ph.D. degree in Biochemistry from Cornell University. He also completed a post-doctoral fellowship at Princeton University.
Lavidas, Athanase Athanase Lavidas, Ph.D. one of Directors of Ariad Pharmaceuticals, Inc. since September 2003 and lead director since November 2008, is the Chairman and Chief Executive Officer of Lavipharm Group, a pharmaceutical, cosmetics and consumer-health products company in Greece, a position he has held since 1976. Dr. Lavidas is also Chairman of the Greece - U.S. Business Council and Secretary General of the Federation of Greek Industries, responsible for International Affairs. He received his B.S. and M.S. degrees from the University of Munich, his M.B.A. from the Institut Superior de Marketing et de Management in Paris, and his Ph.D. from the University of Athens.
LaMarche, Jay Jay R. LaMarche one of Directors of Ariad Pharmaceuticals, Inc. since January 1992, is a retired financial executive. Previously, he served as Chief Financial Officer and Treasurer from January 1992 to November 2000 and as Executive Vice President from March 1997 to November 2000. Mr. LaMarche was Senior Vice President, Finance from January 1992 to February 1997. Prior to joining , he was Chief Financial Officer and a Director of ChemDesign Corporation, a fine chemicals manufacturer. Previously, Mr. LaMarche was a partner with Deloitte Haskins & Sells, a public accounting firm. Mr. LaMarche received his B.B.A. degree in Public Accountancy from the University of Notre Dame and served as an officer in the United States Navy.
Radaelli, Massimo Massimo Radaelli, Ph.D., one of directors of Ariad Pharmaceuticals, Inc. since October 2008, is the President and Chief Executive Officer of Dompé International SA, the international pharmaceutical company of the Dompé Group, where he is responsible for the company’s global sales and export activities. He joined Dompé in 1996 as director of corporate business development and was responsible for the initiation of Dompé’s global strategy in its Swiss subsidiary and for its strategic planning, licensing, alliances and new-product opportunities in Europe. Previously, Dr. Radaelli held various sales and marketing positions at the Dupont-Merck Pharmaceutical Company from 1990 to 1996, the Menarini Group from 1989 to 1990 and Hoffman-La Roche Ltd. from 1982 to 1989. Dr. Radaelli received a University Degree in pharmaceutical sciences and a Ph.D. in clinical pharmacology from the University of Milan and an Executive Master of Business from Bocconi University of Milan.
Wilson, Wayne Wayne Wilson one of directors of Ariad Pharmaceuticals, Inc. since October 2008, has been an independent business advisor since September 2002. From January 1998 to September 2002, Mr. Wilson served as President and Chief Operating Officer and, from August 1995 to January 1998, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer of PC Connection, Inc., a direct marketer of information technology products and services. From June 1986 to August 1995, Mr. Wilson was a partner in the assurance and advisory services practice of Deloitte & Touche LLP. Mr. Wilson is a director of Edgewater Technology, Inc., a technology management consulting company, and Hologic, Inc., a medical diagnostics and device company. Mr. Wilson received an A.B. degree from Duke University and an M.B.A. from the University of North Carolina at Chapel Hill. He is a certified public accountant.
Smyth, A. Collier A. Collier Smyth, M.D one of Directors of Ariad Pharmaceuticals, Inc. since April 2009, is a retired pharmaceutical executive. Most recently, Dr. Smyth served as Senior Vice President of Medical Strategy - Oncology at Bristol-Myers Squibb Company (BMS), a pharmaceutical company, from 2006 until March 2009. Previously, while at BMS, Dr. Smyth was Senior Vice President, Medical Strategy - Oncology/Immunoscience from 2004 to 2006, Senior Vice President, Oncology Medical Affairs from 2000 to 2004, and Vice President, Oncology/Immunology Medical Affairs from 1996 to 2000. Prior to joining BMS, Dr. Smyth served as Vice President, Medical Affairs with American Oncology Resources, Inc., now U.S. Oncology, a cancer health care network, and was the founder and president of New Hampshire Oncology/Hematology, a medical oncology practice. Dr. Smyth received a B.S. degree from Lehigh University and an M.D. degree from Johns Hopkins School of Medicine. He completed his residency in medicine at Beth Israel Hospital, Harvard Medical School and his oncology fellowship at the National Cancer Institute.

Basic Compensation

Name Fiscal Year Total
Berger, Harvey 1,694,700
Fitzgerald, Edward 736,973
Clackson, Timothy 740,402
Keane, Raymond --
Iuliucci, John 792,657
Berstein, David 664,404
Dodion, Pierre 558,946
Ros, Matthew --
Bollag, Daniel --
Lavidas, Athanase --
LaMarche, Jay 223,592
Radaelli, Massimo --
Wilson, Wayne --
Smyth, A. Collier --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Berger, Harvey 1,081,182 2,284,539
Fitzgerald, Edward 243,000 217,350
Clackson, Timothy 229,560 593,115
Keane, Raymond 0 0
Iuliucci, John 447,133 831,075
Berstein, David 409,571 471,691
Dodion, Pierre 0 0
Ros, Matthew 0 0
Bollag, Daniel 0 0
Lavidas, Athanase 0 0
LaMarche, Jay 286,357 1,107,673
Radaelli, Massimo 0 0
Wilson, Wayne 0 0
Smyth, A. Collier 0 0

Insider Trading

Name Shares Traded Price
LAVIDAS ATHANESE 20,000 $0.00
RADAELLI MASSIMO 20,000 $0.00
WILSON WAYNE L 20,000 $0.00
LAMARCHE JAY R 20,000 $0.00
SMYTH A COLLIER 20,000 $0.00
IULIUCCI JOHN D 70,000 $2.16
IULIUCCI JOHN D 70,000 $0.75
BERGER HARVEY J 1,714,286 $1.75
DODION PIERRE F 5,714 $1.75
LAMARCHE JAY R 20,000 $0.00
LAVIDAS ATHANESE 20,000 $0.00
SMYTH A COLLIER 15,000 $0.00
WILSON WAYNE L 20,000 $0.00
RADAELLI MASSIMO 20,000 $0.00
BERGER HARVEY J 235,000 $0.00
BERGER HARVEY J 10,924 $0.00
BERGER HARVEY J 43,696 $0.00
BERGER HARVEY J 10,924 $0.00
BERGER HARVEY J 10,924 $0.00
BERGER HARVEY J 10,924 $0.00
IULIUCCI JOHN D 71,428 $0.00
LAMARCHE JAY R 166,570 $0.00
BERSTEIN DAVID L 28,570 $0.00
BERGER HARVEY J 357,142 $0.00
BERGER HARVEY J 4,478 $0.00
» Full list on Insider Trading
view people for: